Ani Pharmaceuticals Inc. (ANIP)
Why ANI (ANIP) Could Beat Earnings Estimates Again
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Okay. Good Afternoon, everybody.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.
